FOR THE HARD NOSE PUNTERS HAVE A LOOK AT MARKET DEPTH OF CNN .LOOKS LIKE A CLASSIC RECOVERY IN SHARE PRICE IN MY OPINION.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%